Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
First-line treatment with pembrolizumab plus axitinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with advanced clear-cell RCC* who had intermediate/poor IMDC** risk classification, according to updated results of the KEYNOTE-426*** study presented at BASCO 2019 Annual Meeting held in Singapore.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.